Reported Earlier, Guardant Health's Shield Blood Test For Colorectal Cancer Screening Receives Strong Recommendation From FDA Advisory Committee, Paving The Way For Approval
Portfolio Pulse from Benzinga Newsdesk
Guardant Health's Shield blood test for colorectal cancer screening has received a strong recommendation from the FDA advisory committee, paving the way for potential FDA approval. This test offers a convenient, non-invasive screening option and is on track to become the first FDA-approved blood test meeting Medicare coverage requirements.
May 24, 2024 | 6:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health's Shield blood test for colorectal cancer screening has received a strong recommendation from the FDA advisory committee, which could lead to FDA approval. This development positions Shield to become the first FDA-approved blood test meeting Medicare coverage requirements.
The strong recommendation from the FDA advisory committee significantly increases the likelihood of FDA approval for Guardant Health's Shield blood test. This approval would make Shield the first FDA-approved blood test for colorectal cancer screening that meets Medicare coverage requirements, likely boosting Guardant Health's market position and stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100